Journal of Genetic Counseling

, Volume 23, Issue 1, pp 5–15 | Cite as

Molecular Testing for Cystic Fibrosis Carrier Status Practice Guidelines: Recommendations of the National Society of Genetic Counselors

  • Elinor Langfelder-Schwind
  • Barbara Karczeski
  • Michelle N. Strecker
  • Joy Redman
  • Elaine A. Sugarman
  • Christina Zaleski
  • Trisha Brown
  • Steven Keiles
  • Amy Powers
  • Sumheda Ghate
  • Rebecca Darrah
Professional Issues

Purpose

To provide practice recommendations for genetic counselors whose clients are considering cystic fibrosis (CF) carrier testing or seeking information regarding CF molecular test results. The goals of these recommendations are to: 1) Provide updated information about the natural history, diagnosis, and treatment of CF and related conditions. 2) Supplement genetic counselors’ knowledge and understanding of the available carrier screening and diagnostic testing options. 3) Describe the current state of genotype/phenotype correlations for CFTR mutations and an approach to interpreting both novel and previously described variants. 4) Provide a framework for genetic counselors to assist clients’ decision-making regarding CF carrier testing, prenatal diagnosis, and pregnancy management.

Disclaimer The practice guidelines of the National Society of Genetic Counselors (NSGC) are developed by members of the NSGC to assist genetic counselors and other health care providers in making decisions about appropriate management of genetic concerns; including access to and/or delivery of services. Each practice guideline focuses on a clinical or practice-based issue, and is the result of a review and analysis of current professional literature believed to be reliable. As such, information and recommendations within the NSGC practice guidelines reflect the current scientific and clinical knowledge at the time of publication, are only current as of their publication date, and are subject to change without notice as advances emerge.

In addition, variations in practice, which take into account the needs of the individual patient and the resources and limitations unique to the institution or type of practice, may warrant approaches, treatments and/or procedures that differ from the recommendations outlined in this guideline. Therefore, these recommendations should not be construed as dictating an exclusive course of management, nor does the use of such recommendations guarantee a particular outcome. Genetic counseling practice guidelines are never intended to displace a health care provider’s best medical judgment based on the clinical circumstances of a particular patient or patient population.

Practice guidelines are published by NSGC for educational and informational purposes only, and NSGC does not “approve” or “endorse” any specific methods, practices, or sources of information.

Keywords

Cystic fibrosis carrier screening Carrier testing, genetic testing Genetic counseling 

References

  1. American College of Obstetricians and Gynecologists. (2005). Update on carrier screening for cystic fibrosis Committee Opinion No. 325. Obstetrics and Gynecology, 106(6), 1465–1468.CrossRefGoogle Scholar
  2. American College of Obstetricians and Gynecologists. (2011). Update on carrier screening for cystic fibrosis. Committee Opinion No. 486. Obstetrics and Gynecology, 117(4), 1028–1031.CrossRefGoogle Scholar
  3. American College of Obstetricians and Gynecologists, & American College of Medical Genetics. (2001). Preconception and prenatal carrier screening for cystic fibrosis. Clinical and Laboratory Guidelines. American College of Obstetricians and Gynecologists, Washington, DC.Google Scholar
  4. Bobadilla, J. L., Macek, M., Jr., Fine, J. P., & Farrell, P. M. (2002). Cystic fibrosis: a worldwide analysis of CFTR mutations– correlation with incidence data and application to screening. Human Mutation, 19(6), 575–606.CrossRefPubMedGoogle Scholar
  5. Bombieri, C., Claustres, M., De Boeck, K., et al. (2011). Recommendations for the classification of diseases as CFTR-related disorders. Journal of Cystic Fibrosis, 10(Suppl2), S86–S102.CrossRefPubMedGoogle Scholar
  6. Borowitz, D., Parad, R., Sharp, J. K., et al. (2009). Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. Journal of Pediatrics, 155, S106e16.Google Scholar
  7. Buller, A., Olson, S., Redman, J. B., et al. (2004). Frequency of the cystic fibrosis 3199del6 mutation in individuals heterozygous for I148T. Genetics in Medicine, 6(2), 108–109.CrossRefPubMedGoogle Scholar
  8. Carlyle, B. E., Borowitz, D. S., & Glick, P. L. (2012). A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. Journal of Pediatric Surgery, 47(4), 772–781.CrossRefPubMedGoogle Scholar
  9. Castellani, C., Cuppens, H., Macek, M., et al. (2008). Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. Journal of Cystic Fibrosis, 7, 179–196.PubMedCentralCrossRefPubMedGoogle Scholar
  10. Claustres, M., Altiére, J.-P., Guittard, C., et al. (2004). Are p.I148T, p.R74W and p.D1270N cystic fibrosis causing mutations? BMC Medical Genetics, 5, 19.PubMedCentralCrossRefPubMedGoogle Scholar
  11. Cleveland, R. H., Zurakowski, D., Slattery, D., & Colin, A. A. (2009). Cystic fibrosis genotype and assessing rates of decline in pulmonary status. Radiology, 253(3), 813–821.CrossRefPubMedGoogle Scholar
  12. Collaco, J. M., & Cutting, G. R. (2008). Update on gene modifiers in cystic fibrosis. Current Opinion in Pulmonary Medicine, 14(6), 559–566.PubMedCentralCrossRefPubMedGoogle Scholar
  13. Cuppens, H., Lin, W., Jaspers, M., Costes, B., Teng, H., Vankeerberghen, A., et al. (1998). Polyvariant mutant cystic fibrosis transmembrane conductance regulator genes. The polymorphic (Tg)m locus explains the partial penetrance of the T5 polymorphism as a disease mutation. Journal of Clinical Investigation, 101(2), 487–496.PubMedCentralCrossRefPubMedGoogle Scholar
  14. Cystic Fibrosis Foundation. (1997). Clinical practice guidelines. Google Scholar
  15. Cystic Fibrosis Foundation Patient Registry. (2011). Database, accessed 24 April 2013. Bethesda, Maryland.Google Scholar
  16. Cystic Fibrosis Foundation Patient Registry. (2012). 2011 Annual data report.Google Scholar
  17. De Boeck, K., Wilschanski, M., Castellani, C., et al. (2006). Cystic fibrosis: terminology and diagnostic algorithms. Thorax, 61, 627–635.CrossRefPubMedGoogle Scholar
  18. Dequeker, E., Stuhrmann, M., Morris, M. A., et al. (2009). Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders—updated European recommendations. European Journal of Human Genetics, 17(1), 51–65.CrossRefPubMedGoogle Scholar
  19. Di Sant’Agnese, P. A., Darling, R. C., Perera, G. A., & Shea, E. (1953). Sweat electrolyte disturbances associated with childhood pancreatic disease. American Journal of Medicine, 15(6), 777–784.CrossRefGoogle Scholar
  20. Drumm, M. L., Konstan, M. W., Schluchter, M. D., Handler, A., Pace, R., Zou, F., et al. (2005). Gene Modifier Study Group. New England Journal of Medicine, 353(14), 1443–1453.Google Scholar
  21. Eshaque, B., & Dixon, B. (2006). Technology platforms for molecular diagnosis of cystic fibrosis. Biotechnology Advances, 24, 86–93.CrossRefPubMedGoogle Scholar
  22. Farrell, P. M., Kosorok, M. R., Laxova, A., et al. (1997). Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Nutritional benefits of neonatal screening for cystic fibrosis. The New England Journal of Medicine, 337, 963–969.CrossRefPubMedGoogle Scholar
  23. Farrell, P. M., Rosenstein, B. J., White, T. B., et al. (2008). Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. Journal of Pediatrics, 15(3), S4–S14.CrossRefGoogle Scholar
  24. Fiel, S. B. (1996). Pulmonary function during pregnancy in cystic fibrosis: implications for counseling. Current Opinion in Pulmonary Medicine, 2(6), 462–465.PubMedGoogle Scholar
  25. Grody, W. W., Cutting, G. R., Klinger, K. W., et al. (2001). Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genetics in Medicine, 3(2), 149–154.CrossRefPubMedGoogle Scholar
  26. Grody, W. W., Cutting, G. R., & Watson, M. S. (2007). The cystic fibrosis mutation “arms race”: when less is more. Genetics in Medicine, 9(11), 739–744.CrossRefPubMedGoogle Scholar
  27. Groman, J. D., Karczeski, B., Sheridan, M., et al. (2005). Phenotypic and genetic characterization of patients with features of “nonclassic” forms of cystic fibrosis. Journal of Pediatrics, 146(5), 675–680.PubMedCentralCrossRefPubMedGoogle Scholar
  28. Groman, J. D., Hefferon, T. W., Casals, T., et al. (2004). Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. American Journal of Human Genetics, 74(1), 176–179.PubMedCentralCrossRefPubMedGoogle Scholar
  29. Howenstine, M., & Montegomery, G. S. (2009). Cystic fibrosis. Pediatrics in Review, 30, 302–310. doi:10.1542/pir.30-8-302.CrossRefPubMedGoogle Scholar
  30. Jones, A. M., & Helm, J. M. (2009). Emerging treatments in cystic fibrosis. Drugs, 69(14), 1903–1910.CrossRefPubMedGoogle Scholar
  31. Keiles, S., Koepke, R., Parad, R., et al. (2011). Impact of IVS8-(TG)m(T)n on IRT and sweat chloride levels in newborns identified by California CF newborn screening. Journal of Cystic Fibrosis (in press).Google Scholar
  32. Kere, E., Reisman, J., Corey, M., et al. (1992). Prediction of mortality in patients with cystic fibrosis. New England Journal of Medicine, 326(8), 1187–1191.CrossRefGoogle Scholar
  33. Kiesewetter, S., Macek, M., Jr., Davis, C., et al. (1993). A mutation in CFTR produces different phenotypes depending on chromosomal background. Nature Genetics, 5(3), 274–278.CrossRefPubMedGoogle Scholar
  34. Koscik, R. L., Lai, H., Laxova, A., et al. (2005). Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. Journal of Pediatrics, 147(3 Suppl), S51–S56.CrossRefPubMedGoogle Scholar
  35. Langfelder-Schwind, E., Kloza, E., Sugarman, E., et al. (2005). Cystic fibrosis prenatal screening in genetic counseling practice: recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling, 14(1), 1–15.CrossRefPubMedGoogle Scholar
  36. Lebo, R. V., & Grody, W. W. (2007). Testing and reporting ACMG cystic fibrosis mutation panel results. Genetic Testing, 11(1), 11–31.CrossRefPubMedGoogle Scholar
  37. Massie, R. J., Poplawski, N., Wilcken, B., et al. (2001). Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. European Respiratory Journal, 17(6), 1195–1200.CrossRefPubMedGoogle Scholar
  38. Massie, R. J. H., Curnow, L., Glazner, J., et al. (2012). Lessons learned from 20 years of newborn screening for cystic fibrosis. The Medical Journal of Australia, 196(1), 67–70.CrossRefPubMedGoogle Scholar
  39. McKone, E. F., Emerson, S. S., Edwards, K. L., & Aitken, M. L. (2003). Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet, 361(9370), 1671–1676.CrossRefPubMedGoogle Scholar
  40. McKone, E. F., Goss, C. H., & Aitken, M. L. (2006). CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest, 130(5), 1441–1447.CrossRefPubMedGoogle Scholar
  41. Mehta, G., Macek, M., Jr., Mehta, A., & European Registry Working Group. (2010). Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. Journal of Cystic Fibrosis, 9(Suppl 2), S5–S21.CrossRefPubMedGoogle Scholar
  42. Mérelle, M. E., Scheffer, H., DeJong, D., & Dankert-Roelse, J. E. (2006). Extended gene analysis can increase specificity of neonatal screening for cystic fibrosis. Acta Paediatrica, 95, 1424–1428.CrossRefPubMedGoogle Scholar
  43. Mickle, J. E., & Cutting, G. R. (1998). Clinical implications of cystic fibrosis transmembrane conductance regulator mutations. Clinics in Chest Medicine, 19(3), 443–458.CrossRefPubMedGoogle Scholar
  44. Monaghan, K. G., Highsmith, W. E., Amos, J., et al. (2004). Genotype-phenotype correlation and frequency of the 3199del6 cystic fibrosis mutation among I148T carriers: results from a collaborative study. Genetics in Medicine, 6(5), 421–425.CrossRefPubMedGoogle Scholar
  45. Moran, A., Brunzell, C., Cohen, R. C., et al. (2010). CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes. Diabetes Care, 33(12), 2697–2708.CrossRefPubMedGoogle Scholar
  46. Morton, J., & Glanville, A. R. (2009). Lung transplantation in patients with cystic fibrosis. Seminars in Respiratory and Critical Care Medicine, 30(5), 559–568.CrossRefPubMedGoogle Scholar
  47. Moskowitz, S. M., Chmiel, J. F., Sternen, D. L., et al. (2008). Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genetics in Medicine, 10(12), 851–868.PubMedCentralCrossRefPubMedGoogle Scholar
  48. Mussaffi, H., Prais, D., Mei-Zahav, M., & Blau, H. (2006). Cystic fibrosis mutations with widely variable phenotype: the D1152H example. Pediatric Pulmonology, 41(3), 250–254.CrossRefPubMedGoogle Scholar
  49. Ogino, S., Wilson, R. B., & Grody, W. W. (2004). Bayesian risk assessment for autosomal recessive diseases: fetal echogenic bowel with one or not detectable CFTR mutation. Journal of Medical Genetics, 41(5), e70.CrossRefPubMedGoogle Scholar
  50. O’Neill, S. C., DeMarco, T., Peshkin, B. N., et al. (2006). Tolerance for uncertainty and perceived risk among women receiving uninformative BRCA1/2 test results. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 142C(4), 251–259.CrossRefPubMedGoogle Scholar
  51. Palomaki, G. E., FitzSimmons, S. C., & Haddow, J. E. (2004). Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genetics in Medicine, 6(5), 405–414.CrossRefPubMedGoogle Scholar
  52. Quittner, A. L., Modi, A., & Cruz, I. (2008). Systematic review of health-related quality of life measures for children with respiratory conditions. Paediatric Respiratory Reviews, 9(3), 220–232.CrossRefPubMedGoogle Scholar
  53. Rohlfs, E. M., Sugarman, E. A., Heim, R. A., & Allitto, B. A. (2001). Frequency of carriers of two cystic fibrosis mutations in an apparently unaffected adult population. Genetics in Medicine, 3, 237.Google Scholar
  54. Rohlfs, E. M., Zhou, Z., Sugarman, E. A., et al. (2002). The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis. Genetics in Medicine, 4(5), 319–323.CrossRefPubMedGoogle Scholar
  55. Rohlfs, E. M., Zhou, Z., Heim, R. A., et al. (2011). Cystic fibrosis carrier testing in an ethnically diverse US population. Clinical Chemistry, 57(6), 841–848.CrossRefPubMedGoogle Scholar
  56. Rosenstein, B. J., & Cutting, G. R. (1998). The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation consensus panel. Journal of Pediatrics, 132(4), 589–595.CrossRefPubMedGoogle Scholar
  57. Sawicki, G. S., Rasouliyan, L., McMullen, A. H., et al. (2010). Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatric Pulmonology, 46(1), 36–44.CrossRefPubMedGoogle Scholar
  58. Schibli, S., Durie, P. R., & Tullis, E. D. (2002). Proper usage of pancreatic enzymes. Current Opinion in Pulmonary Medicine, 8, 542–546.CrossRefPubMedGoogle Scholar
  59. Schlegel, P. N., Cohen, J., Goldstein, M., et al. (1995). Cystic fibrosis gene mutations do not affect sperm function during in vitro fertilization with micromanipulation for men with bilateral congenital absence of vas deferens. Fertility and Sterility, 64(2), 421–426.PubMedGoogle Scholar
  60. Sebro, R., Levy, H., Schneck, K., et al. (2012). Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency. Clinical Genetics, 82, 546–551.CrossRefPubMedGoogle Scholar
  61. Smith, H. C. (2010). Fertility in men with cystic fibrosis assessment, investigations and management. Paediatric Respiratory Reviews, 11(2), 80–83.CrossRefPubMedGoogle Scholar
  62. Sosnay, P. R., Castellani, C., Corey, M., et al. (2011). Evaluation of the disease liability of CFTR variants. Methods in Molecular Biology, 742, 355–372.CrossRefPubMedGoogle Scholar
  63. Strom, C. M., Huang, D., Chen, C., et al. (2003). Extensive sequencing of the cystic fibrosis transmembrane regulator gene: assay validation and unexpected benefits of developing a comprehensive test. Genetics in Medicine, 5(1), 9–14.CrossRefPubMedGoogle Scholar
  64. Svensson, A. M., Chou, L. S., Miller, C. E., et al. (2010). Detection of large rearrangements in the cystic fibrosis transmembrane conductance regulator gene by multiplex ligation-dependent probe amplification assay when sequencing fails to detect two disease-causing mutations. Genetic Testing and Molecular Biomarkers, 14(2), 171–174.CrossRefPubMedGoogle Scholar
  65. Taylor, C. J., Hardcastle, J., & Southern, K. W. (2009). Physiological measurements confirming the diagnosis of cystic fibrosis: the sweat test and measurements of transepithelial potential difference. Paediatric Respiratory Reviews, 10(4), 220–226.CrossRefPubMedGoogle Scholar
  66. Thauvin-Robinet, C., Munck, A., Huet, F., et al. (2009). Collaborating Working Group on R117H. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counseling and newborn screening. Journal of Medical Genetics, 46(11), 752–758.CrossRefPubMedGoogle Scholar
  67. Tluczek, A., Zaleski, C., Stachiw-Hietpas, D., et al. (2011). A tailored approach to family-centered genetic counseling for cystic fibrosis newborn screening: the Wisconsin model. Journal of Genetic Counseling, 20(2), 115–128.PubMedCentralCrossRefPubMedGoogle Scholar
  68. Uhlmann, W. (2009). Thinking it all through: Case preparation and management. In D. L. Baker, J. L. Schuette, & W. Uhlmann (Eds.), A guide to genetic counseling (2nd ed., pp. 108–110). New York: Wiley-Liss, Inc.Google Scholar
  69. Vanscoy, L. L., Blackman, S. M., Collaco, J. M., Bowers, A., Lai, T., Naughton, K., et al. (2007). American Journal of Respiratory and Critical Care Medicine, 175(10), 1036–1043.CrossRefPubMedGoogle Scholar
  70. Waters, D. L., Wilcken, B., Irwig, L., et al. (1999). Clinical outcomes of newborn screening for cystic fibrosis. Archives of Disease in Childhood. Fetal and Neonatal Edition, 80(1), F1–F7.CrossRefPubMedGoogle Scholar
  71. Watson, M. S., Cutting, G. R., Desnick, R. J., et al. (2004). Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genetics in Medicine, 6(5), 387–391.PubMedCentralCrossRefPubMedGoogle Scholar
  72. Weil, J. (Ed.). (2000). Psychosocial genetic counseling (pp. 133–134). New York: Oxford University Press.Google Scholar
  73. Zielenski, J. (2000). Genotype and phenotype in cystic fibrosis. Respiration, 67(2), 117–133.CrossRefPubMedGoogle Scholar
  74. Whittey, J. E. (2010). Cystic fibrosis in pregnancy. Clinical Obstetrics and Gynecology, 53(2), 369–376.CrossRefGoogle Scholar

Copyright information

© National Society of Genetic Counselors, Inc. 2013

Authors and Affiliations

  • Elinor Langfelder-Schwind
    • 1
  • Barbara Karczeski
    • 2
  • Michelle N. Strecker
    • 3
  • Joy Redman
    • 4
  • Elaine A. Sugarman
    • 5
  • Christina Zaleski
    • 6
    • 7
  • Trisha Brown
    • 8
  • Steven Keiles
    • 9
  • Amy Powers
    • 10
  • Sumheda Ghate
    • 11
  • Rebecca Darrah
    • 12
  1. 1.Beth Israel Medical CenterNew YorkUSA
  2. 2.DNA Diagnostic LaboratoryJohns Hopkins UniversityBaltimoreUSA
  3. 3.CombiMatrix DiagnosticsIrvineUSA
  4. 4.Quest DiagnosticsSan Juan CapistranoUSA
  5. 5.Integrated GeneticsWestboroughUSA
  6. 6.Marshfield ClinicMarshfieldUSA
  7. 7.Prevention GeneticsMarshfieldUSA
  8. 8.Shama ConsultingClaytonUSA
  9. 9.Ambry GeneticsAliso ViejoUSA
  10. 10. University of Minnesota Medical Center, FairviewMinneapolisUSA
  11. 11.St. Vincent’s HospitalGreen BayUSA
  12. 12.Case Western Reserve UniversityClevelandUSA

Personalised recommendations